Journal article · 2026 · Open access

Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis

Tat Ming Ng, Bernice Xin Ting Chan, Jiafang Chen, Angelyn Shu Min Tan, Ziteng Wang, Arjun Kolappurath Madathil, Annabel Xing Rong Chua, Barnaby Young, Eric Chun Yong Chan

Clinical Pharmacology & Therapeutics · Published 14 November 2026 · DOI 10.1002/cpt.70572

Open PDFView at the publisherCite this paper

In brief

“Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis” is a 2026 journal article by Tat Ming Ng and 8 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 18 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
22
Authors
9

Abstract

While nirmatrelvir-ritonavir effectively prevents severe COVID-19, its ritonavir component causes significant drug-drug interactions (DDIs). Current guidelines suggest mitigating this interaction by halving the amlodipine dose or moving to every-other-day (EOD) dosing, then resuming the standard regimen 3-5 days post-antiviral treatment. We applied physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) modeling to evaluate the effects of these recommendations on systolic blood pressure (SBP) control. SARS-CoV-2 inpatients who received nirmatrelvir-ritonavir (October-December 2022) and were exposed to potential DDIs were identified. An amlodipine PBPK-PD model incorporating the diurnal variation of SBP was developed. The model was validated using amlodipine PK studies, including in DDI scenarios, while the PD model was validated against SBP data collected during amlodipine treatment. Simulations were performed in representative virtual populations, comprising various amlodipine doses and regimens, during and after nirmatrelvir-ritonavir therapy. 362/1729 (20.9%) drugs from 166/217 (76.5%) patients were identified to have potential DDIs implicating nirmatrelvir-ritonavir. Amlodipine was a common interacting drug (64/362, 17.7%) and often prescribed without dose adjustment (63%). Our simulations supported that continuing amlodipine during therapy may lead to SBP ≤100 mmHg at daily doses of ≥5 mg, while discontinuation may lead to SBP >130-150 mmHg. Halving the amlodipine dose during nirmatrelvir-ritonavir treatment could provide more stable SBP control than EOD dosing. Resuming usual doses 3 days after nirmatrelvir-ritonavir could be more important in those receiving 7.5 and 10 mg of amlodipine. DDIs between nirmatrelvir-ritonavir and amlodipine were common. Our simulations evaluated current dose adjustment recommendations for amlodipine with mechanistic quantitative reasoning.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ng, T. M., Chan, B. X. T., Chen, J., Tan, A. S. M., Wang, Z., Madathil, A. K., Chua, A. X. R., Young, B., & Chan, E. C. Y. (2026). Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70572

MLA 9

Ng, Tat Ming, et al. “Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70572.

Chicago

Ng, Tat Ming, Bernice Xin Ting Chan, Jiafang Chen, Angelyn Shu Min Tan, Ziteng Wang, Arjun Kolappurath Madathil, Annabel Xing Rong Chua, Barnaby Young, and Eric Chun Yong Chan. 2026. “Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70572.

Harvard

Ng, T. M. et al. (2026) ‘Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70572.

IEEE

T. M. Ng et al., “Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70572.

BibTeX

@article{ng2026model,
  title     = {{Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis}},
  author    = {Ng, Tat Ming and Chan, Bernice Xin Ting and Chen, Jiafang and Tan, Angelyn Shu Min and Wang, Ziteng and Madathil, Arjun Kolappurath and Chua, Annabel Xing Rong and Young, Barnaby and Chan, Eric Chun Yong},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70572},
  url       = {https://doi.org/10.1002/cpt.70572}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • amlodipine
  • nirmatrelvir/ritonavir
  • drug-drug interactions
  • ritonavir
  • systolic blood pressure control
  • COVID-19 antiviral therapy
  • virtual population

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Ng, T. M., Chan, B. X. T., Chen, J., Tan, A. S. M., Wang, Z., Madathil, A. K., Chua, A. X. R., Young, B., & Chan, E. C. Y. (2026). Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70572

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Tat Ming Ng, Bernice Xin Ting Chan, Jiafang Chen, Angelyn Shu Min Tan, Ziteng Wang, Arjun Kolappurath Madathil, Annabel Xing Rong Chua, Barnaby Young, Eric Chun Yong Chan.

What is the DOI of this paper?

10.1002/cpt.70572, permanently at https://doi.org/10.1002/cpt.70572. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.